UPS, FedEx and DHL Bet Billions on Weight-Loss Drugs 💊

They say some of the biggest stories hide in plain sight. One of them was buried in a press release from an American logistics company that has been moving freight for 121 years.

On March 17, 2026, C.H. Robinson issued a brief press release with a number that was easy to glance over and harder to ignore once you noticed it. The Minnesota-based logistics giant said its healthcare logistics business had generated more than $1 billion in revenue over the previous 12 months.

The figure was striking enough. But the sentence that followed was more revealing: C.H. Robinson said the milestone put it among a select group of global third-party logistics providers to have built a healthcare business of that scale.

For a company that moves almost everything else, something very specific was beginning to move very fast: and that was the bigger story. 

At a time when the broader freight market was struggling for growth, C.H. Robinson was building a billion-dollar business around moving medicines – through a supply chain that demands temperature-controlled transportation, specialized handling and precise delivery. 

Much of this rapid growth was driven by one powerful force: glucagon-like peptide-1 (GLP-1) drugs, commonly known as GLP-1s, which have rapidly become synonymous with weight loss. 

But their impact extends far beyond the human body. GLP-1s are beginning to reshape American logistics, too.

So how is the rapid rise of GLP-1 medicines reshaping the American logistics landscape? To understand that, we first need to look at the drugs themselves and why demand for them has grown so quickly in recent years.

The story of GLP-1s began more than four decades ago, and it had nothing to do with weight loss.

In 1982, scientists discovered GLP-1 while studying how the body controls blood sugar. Over the next two decades, researchers worked on turning that discovery into a medicine. In 2005, the first GLP-1 drug was approved to help people with type 2 diabetes.

Then they noticed something else: people taking these drugs were losing weight.

That changed everything. Drugmakers began testing GLP-1s for weight loss, and Novo Nordisk had already positioned itself at the center of the market with two names: Ozempic, approved for type 2 diabetes in 2017, and Wegovy, approved specifically for weight management in 2021.

Then came 2022, the year GLP-1s broke into the mainstream.

Ozempic’s weight-loss effects began attracting enormous public attention, while Wegovy was entering the market as a drug specifically designed for obesity. Social media, celebrity use and growing word-of-mouth helped push GLP-1s far beyond the diabetes market, turning them into a mainstream weight-loss phenomenon.

The numbers show just how quickly that happened. According to a 2025 study published in the Annals of Internal Medicine, the number of U.S. adults without diabetes using GLP-1 drugs for weight loss more than tripled between 2018 and 2022, rising from about 259,000 to 855,000 people. Annual spending on these medications surged from $1.6 billion to $5.8 billion over the same period — a 262% increase in just four years.

The surge in demand quickly translated into billions of dollars in sales for drugmakers.

At the center of it was Novo Nordisk. According to the company's 2022 Annual Report, sales of its GLP-1 diabetes medicines rose 56% to approximately $11.8 billion (DKK 83.4 billion). Its obesity-care business, led by Wegovy and Saxenda, grew even faster, with sales jumping 84% to approximately $2.4 billion (DKK 16.9 billion).

Its competitors also wanted a piece of the pie. Eli Lilly entered the race with Mounjaro in 2022, and despite launching midway through the year, the drug generated $279.2 million in sales in the fourth quarter alone, according to the company's earnings report.

Fast forward to 2026, and GLP-1s have become one of the fastest-growing drug categories in history. According to Gallup, 11% of U.S. adults now use a GLP-1 medication for weight loss, while 15% say they have taken one at some point. What began as a treatment for type 2 diabetes has evolved into a mainstream consumer product. In fact, in 2025, Eli Lilly became the world's first pharmaceutical company to reach a $1 trillion market valuation, driven largely by the extraordinary demand for its GLP-1 medicines. And the growth is far from over. According to GlobalData, the global GLP-1 market is projected to reach approximately $125 billion by 2033. 

The economic implications could extend well beyond the healthcare industry. According to a Washington Post report, Jan Hatzius, Chief Economist at Goldman Sachs, estimates that if 60 million Americans adopt GLP-1 weight-loss drugs by 2028, it could increase U.S. GDP by approximately 1%, driven by a healthier workforce, higher productivity, and lower healthcare costs.

But before any of this can happen, every one of those drugs has to make a journey before it reaches a patient. And that's where the logistics story begins.

Unlike most medicines, GLP-1 drugs cannot simply be boxed, loaded onto a truck and delivered.

Most injectable GLP-1 medicines — including Ozempic, Wegovy, Mounjaro and Zepbound — are drugs made from complex peptides. These molecules are highly sensitive to temperature fluctuations. Excessive heat can reduce their potency, while freezing can permanently damage the medicine. Once that happens, the drug cannot be restored.

That is why every shipment must move through a tightly controlled cold chain from the manufacturing plant to wholesalers, distributors, pharmacies and, ultimately, the patient.

According to the U.S. Food and Drug Administration (FDA)-approved prescribing information, Wegovy and Ozempic pens must be refrigerated at 2°C to 8°C (36°F to 46°F), must never be frozen, and should be protected from light by remaining in their original cartons until use. 

Those requirements may sound simple. In reality, they create an entirely different logistics operation.

Every stage of the journey — from refrigerated warehouses and temperature-controlled trucks to insulated packaging, gel packs, temperature-monitoring devices and expedited last-mile delivery — must ensure the medicine remains within its approved storage conditions. A delayed shipment, a refrigeration failure, or exposure to freezing temperatures can render an entire shipment unusable.

That is precisely why the GLP-1 boom has become a logistics opportunity. Every additional patient means another temperature-sensitive shipment that has to be stored, transported, and delivered without compromising the shipment. In short, as long as demand continues to climb for GLP-1s, so will the need for sophisticated cold-chain infrastructure, and logistics companies do not want to let go of this gold rush. 

As COVID-19 vaccines rolled out in 2020 and 2021, logistics companies raced to build the infrastructure needed to store, transport, and deliver billions of temperature-sensitive doses. The investments went far beyond the immediate crisis—they laid the foundation for the next generation of pharmaceutical logistics.

In 2021, Wes Wheeler, then President of UPS Healthcare, said the pandemic had prompted the company to accelerate its cold-chain investments. "The pandemic caused UPS to move even faster to enhance an integrated set of cold chain solutions to support the future of the pharmaceutical and medical device industry," he said.

Others were making similar bets. For example, in 2022, DHL Supply Chain committed $400 million to expand its U.S. pharmaceutical and medical-device distribution network, adding nearly 3 million square feet across six new facilities with temperature-controlled storage and distribution capabilities

Yes, those investments built a far deeper pharmaceutical logistics network, but the industry is now confronting a very different kind of demand.

COVID-19 vaccines had to reach billions of people, but they were part of a largely time-bound vaccination campaign. GLP-1 drugs are different. Patients don't take them once; they take them week after week, month after month, often for years. That changes the equation completely. Logistics companies are now once again racing to invest, expand capacity, and capture this opportunity. 

Let’s start with UPS. 

In June 2026, the company announced a $48 million investment to expand its global cold-chain network, adding 27 temperature-controlled cross-dock facilities across key markets in the Americas, Europe and Asia. These facilities are designed to reduce handoffs, shorten transit times and maintain an unbroken chain of custody for temperature-sensitive medicines like GLP-1s. 

But UPS is not relying on organic investments alone. In November 2025, it completed the $1.6 billion acquisition of Andlauer Healthcare Group (AHG), one of North America's leading healthcare logistics providers. The deal brought UPS a specialized network of temperature-controlled transportation, healthcare warehousing, and third-party logistics capabilities built specifically for pharmaceutical products. 

More importantly, it strengthened UPS's ability to offer end-to-end cold-chain services across North America at a time when demand for biologics and GLP-1 drugs is accelerating.

The acquisitions and investments build on a business that has been gaining momentum for years. Speaking on UPS's first-quarter 2026 earnings call, CEO Carol Tomé said the company's global healthcare portfolio had gained market share every year since 2021, culminating in its first-ever $3 billion healthcare revenue quarter. "We built a world-class, end-to-end logistics network to handle the most complex time- and temperature-sensitive health care products," she told analysts. 

FedEx is making a similar pivot. 

Recognizing the rapid growth of pharmaceutical logistics, the parcel giant has begun reorganizing its healthcare business into a dedicated vertical, treating it as a strategic growth engine rather than just another customer segment. 

In 2026, FedEx launched FedEx Life Science, a specialized organization bringing together its healthcare logistics capabilities under a single umbrella. The move is designed to provide end-to-end services for pharmaceutical manufacturers, from temperature-controlled transportation and warehousing to customs clearance and last-mile delivery. As more biologics and GLP-1 medicines move through global supply chains, FedEx is positioning itself to handle increasingly complex, time- and temperature-sensitive shipments.

And the scale of the business is already significant. FedEx exited fiscal 2026 with nearly $10 billion in healthcare transportation revenue, up from $9 billion in fiscal 2025.

DHL is making an even bigger bet on the pharmaceutical supply chain.

The latest example sits just outside Los Angeles International Airport, where DHL Global Forwarding is expanding its cold-storage capacity with a $1.5 million investment. The location matters: LAX is a major gateway for trade across the U.S. and the Americas, giving DHL a strategically placed node for moving temperature-sensitive pharmaceutical shipments through the region. The expanded facility will add cold-storage capacity and use real-time temperature monitoring and digital controls to manage products that cannot afford a break in the cold chain.

But the LAX investment is only the visible edge of a much larger strategy. DHL plans to invest €2 billion in health logistics through 2030, with half of that investment going to the Americas. 

But the logistics companies are not the only ones expanding around the GLP-1 boom. The pharmaceutical distributors sitting between drugmakers and pharmacies are scaling up too.

Cencora, one of the largest drug distributors in the U.S., plans to invest $1 billion through 2030 to expand its pharmaceutical distribution network. The investment includes a new 530,000-square-foot national distribution center in Ohio, a 430,000-square-foot facility in California, and a major expansion of refrigerated and frozen storage in Alabama. Cencora says the Alabama project will increase its refrigerated capacity by 500% and frozen capacity by 200%, as demand for specialty medicines grows.

Interestingly, the race to capture the GLP-1 boom is no longer confined to the industry's biggest names.

If the biggest companies are splurging on new facilities and beefing up their infrastructure to capture the GLP-1 boom, smaller and mid-sized players are moving in too. They may not have the scale of UPS, FedEx, or DHL, but they are investing in specialized cold-chain capacity to capture a piece of the same demand. Take GEODIS, for example.

In April 2026, GEODIS opened its first dedicated healthcare cold-chain cross-dock facility in the Americas in Chicago, a 78,000-square-foot bonded facility near O’Hare that includes 5,200 square feet of temperature-controlled space for pharmaceutical imports and exports. Rather than trying to replicate the scale of the global integrators, GEODIS is carving out a more specialized position around healthcare shipments that need controlled handling and faster movement through the network.

Other specialists are going after even narrower pieces of the opportunity. Nordic Cold Chain Solutions, a U.S.-based cold-chain packaging company, has developed a GLP-1 Express Pack specifically for drugs such as semaglutide and tirzepatide.

Another company, Meridian Cold Chain Supply, is taking a similar approach. It sells insulated boxes, liners and mailers specifically designed for GLP-1 shipments, with configurations validated for 24-, 48- and 72-hour temperature protection.

Interestingly, another shift is taking shape at the very end of the supply chain. As employers pull back on GLP-1 coverage, more patients are turning to direct-to-consumer programs for access. The old model—visit a doctor, pick up a prescription at the local pharmacy—is giving way to a new one where consultation, prescription, and delivery can all happen through the same platform.

And that is opening the door for some of America’s biggest retailers.

Let’s start with one of America’s biggest retailers: Walmart. The company is positioning itself as more than a place to pick up a GLP-1 prescription. Through its partnership with LillyDirect, patients can access eligible Lilly medicines through Walmart Pharmacy, with more than 4,600 Walmart pharmacies serving as pickup points across the country. 

Walmart says its pharmacy network can provide same-day medication delivery in as little as an hour in many locations, with free delivery available to Walmart+ members. Interestingly, Walmart is also building a broader system around the prescription. In April 2026, it expanded its Better Care Services platform to bring virtual care, nutrition support, and pharmacy services together. The strategy is clear: capture more of the GLP-1 patient journey, from getting the prescription to filling it and having it delivered. 

Amazon, on the other hand, is ramping up its game to compete directly with Walmart. In April 2026, the company launched a GLP-1 management program through Amazon One Medical and Amazon Pharmacy, bringing consultation, prescription fulfillment and delivery onto the same platform. Eligible patients can access GLP-1s for as little as $25 a month, with same-day delivery available in nearly 3,000 cities, a number Amazon plans to expand to 4,500 by the end of 2026. 

Other retailers, including Costco and CVS, are also positioning themselves to capture the growing GLP-1 demand. Costco is tying GLP-1 access to its membership model through its partnership with Sesame, while CVS is participating in NovoCare and other programs to keep patients within its pharmacy network.

But why are retailers so eager to get into the GLP-1 business? There are two reasons.

The first is frequency. A GLP-1 prescription is not a one-time purchase. Patients need regular refills, which gives retailers a recurring touchpoint with the same customer month after month. That makes the prescription much more valuable than the sale itself.

The second is what GLP-1s are doing to retail itself. As people lose weight, some of their spending can shift away from categories such as groceries, snacks and impulse purchases. A June 2026 PwC survey found that households with a GLP-1 user were spending 5.5% less on groceries, as shoppers cut back on snacks, sugary drinks and alcohol and shifted toward fresh produce, protein and supplements.

In fact, retailers are trying to turn this potential setback into an opportunity. They are looking at the other side of the equation: if one part of the customer's spending is shrinking, the GLP-1 prescription can become a new way to capture that customer and redirect spending elsewhere.

There is another side to the GLP-1 effect on retail, and it starts after the sale.

As people lose weight, their wardrobes change too. Customers may need smaller sizes within weeks, leading to more exchanges and returns. According to Narvar's review of 38 retailers, the share of apparel exchanges in which customers sized down reached 14.6% in 2025, the highest level in the three years studied.

The impact can become significant for retailers. For a company generating $1 billion in annual sales with a 20% return rate, a 5- to 10-percentage-point increase in returns could reduce gross margins by $20 million, according to the analysis cited by the Wall Street Journal.

And every one of those returns creates another logistics journey. The product has to be picked up, transported back, inspected, repackaged, and either returned to inventory or routed into liquidation or resale.

COVID-19 forced logistics companies to build one of the world's most sophisticated cold-chain networks almost overnight. But vaccines were a once-in-a-generation event. GLP-1 drugs are different. In many ways, they are turning the cold chain from a pandemic-era investment into a long-term business.

That is perhaps the biggest logistics story behind the GLP-1 boom. The opportunity is no longer just about transporting refrigerated medicines; it is about creating recurring demand for one of logistics' most specialized and highest-value networks. Every new patient adds another shipment, another temperature-controlled journey and another reason to expand cold-chain capacity.

The winners, therefore, won't be limited to just the big players. Regional cold-chain carriers, specialized healthcare 3PLs, packaging companies, temperature-monitoring providers and last-mile specialists all have an opportunity to carve out profitable niches in an ecosystem that is only beginning to take shape.

For most people, GLP-1s are a story about losing weight. For the logistics industry, they may ultimately be remembered for something else entirely: giving new life to the cold chain.

This newsletter was written by Shyam Gowtham